Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
06:00am, Tuesday, 23'rd Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has upda
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
06:00am, Thursday, 18'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Friday, 12'th Jun 2026
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
12:52pm, Monday, 08'th Jun 2026
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.
AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stag
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
03:36pm, Wednesday, 03'rd Jun 2026
Most investors' portfolios hold at least a couple of the market's biggest companies, just because these names are best-known to most investors. These crowded trades in already-massive companies, howev
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
08:00am, Wednesday, 03'rd Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to t
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
02:12pm, Monday, 01'st Jun 2026
Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.
Why Natera Is My Favorite Stock Idea for the Rest of 2026
10:26am, Friday, 29'th May 2026
It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
06:00am, Friday, 29'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions
12:06pm, Thursday, 28'th May 2026
NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
06:00am, Thursday, 28'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionA
Baron Health Care Fund Q1 2026 Portfolio Activity
03:16pm, Wednesday, 27'th May 2026
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides test
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
07:34am, Wednesday, 27'th May 2026
Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting str
